Chuck Royce's SYRE Position Overview
Chuck Royce (via Royce & Associates Lp) currently holds 51,789 shares of Spyre Therapeutics, Inc. (SYRE) worth $4.6 M, representing 0.04% of the portfolio. First purchased in 2026-Q2, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Chuck Royce has initiated a new position in SYRE, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Chuck Royce's Spyre Therapeutics (SYRE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Spyre Therapeutics (SYRE) Trades by Chuck Royce
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +51,789 | New Buy | 51,789 | $88.78 |
Chuck Royce's Spyre Therapeutics Investment FAQs
Chuck Royce first purchased Spyre Therapeutics, Inc. (SYRE) in Q2 2026, acquiring 51,789 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Chuck Royce has held Spyre Therapeutics, Inc. (SYRE) for 1 quarters since Q2 2026.
Chuck Royce's largest addition to Spyre Therapeutics, Inc. (SYRE) was in Q2 2026, adding 51,789 shares worth $4.6 M.
According to the latest 13F filing for Q2 2026, Chuck Royce's firm, Royce & Associates Lp, owns 51,789 shares of Spyre Therapeutics, Inc. (SYRE), valued at approximately $4.6 M.
As of the Q2 2026 filing, Spyre Therapeutics, Inc. (SYRE) represents approximately 0.04% of Chuck Royce's publicly disclosed stock portfolio, making it one of their key holdings.
Chuck Royce's peak holding in Spyre Therapeutics, Inc. (SYRE) was 51,789 shares, as reported at the end of Q2 2026.